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Abstract
Background: Several association studies have shown that -844 G/A and HindIII C/G PAI-1 polymorphisms are
related with increase of PAI-1 levels, obesity, insulin resistance, glucose intolerance, hypertension and dyslipidemia,
which are components of metabolic syndrome. The aim of this study was to analyze the allele and genotype
frequencies of these polymorphisms in PAI-1 gene and its association with metabolic syndrome and its
components in a sample of Mexican mestizo children.
Methods: This study included 100 children with an age range between 6-11 years divided in two groups: a) 48
children diagnosed with metabolic syndrome and b) 52 children metabolically healthy without any clinical and
biochemical alteration. Metabolic syndrome was defined as the presence of three or more of the following criteria:
fasting glucose levels ≥ 100 mg/dL, triglycerides ≥ 150 mg/dL, HDL-cholesterol < 40 mg/dL, obesity BMI ≥ 95
th
percentile, systolic blood pressure (SBP) and diastolic blood pressure (DBP) ≥ 95
th percentile and insulin resistance
HOMA-IR ≥ 2.4. The -844 G/A and HindIII C/G PAI-1 polymorphisms were analyzed by PCR-RFLP.
Results: For the -844 G/A polymorphism, the G/A genotype (OR = 2.79; 95% CI, 1.11-7.08; p = 0.015) and the A
allele (OR = 2.2; 95% CI, 1.10-4.43; p = 0.015) were associated with metabolic syndrome. The -844 G/A and A/A
genotypes were associated with increase in plasma triglycerides levels (OR = 2.6; 95% CI, 1.16 to 6.04; p = 0.02),
decrease in plasma HDL-cholesterol levels (OR = 2.4; 95% CI, 1.06 to 5.42; p = 0.03) and obesity (OR = 2.6; 95% CI,
1.17-5.92; p = 0.01). The C/G and G/G genotypes of the HindIII C/G polymorphism contributed to a significant
increase in plasma total cholesterol levels (179 vs. 165 mg/dL; p = 0.02) in comparison with C/C genotype.
Conclusions: The -844 G/A PAI-1 polymorphism is related with the risk of developing metabolic syndrome, obesity
and atherogenic dyslipidemia, and the HindIII C/G PAI-1 polymorphism was associated with the increase of total
cholesterol levels in Mexican children.
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Background
Metabolic syndrome (MetS) is a common disorder
caused by a combination of poor diet, sedentary lifestyle
and genetic predisposition [1], the presence of MetS in
children is the main risk factor that predisposes to the
development of cardiovascular and metabolic diseases
such as atherosclerosis and type 2 diabetes mellitus in
adulthood [2]. The components of MetS include obesity,
insulin resistance, hyperglycemia, atherogenic dyslipide-
mia, and hypertension [1,3,4]. Besides these components,
a decrease in fibrinolytic capacity has been shown to
contribute to the development of this syndrome, which
has been generally attributed to increased levels of plas-
minogen activator inhibitor-1 (PAI-1) [5,6].
PAI-1 is the main inhibitor in the plasminogen activa-
tion system (PAS), which comprises an inactive proen-
zyme, plasminogen, which can be converted into its
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minogen activators (PAs). PAs degrades fibrin into solu-
ble products, being PAI-1 one of the main regulators of
fibrinolysis [7]. Increased PAI-1 levels in plasma are asso-
ciated with the development of myocardial infarction and
the formation/progression of chronic inflammatory dis-
eases such as atherosclerosis and cardiovascular disease
[8,9]. Increased of PAI-1 levels also have been linked
with risk factors such as obesity, insulin resistance, glu-
cose intolerance, hypertension and dyslipidemia (low
HDL plasma levels and hypertriglyceridemia), which
together are components of metabolic syndrome [10-13].
The human PAI-1 gene is ~ 12.2 kb long, contains nine
exons and 8 introns, and is located on chromosome
7q22. To date about 180 single nucleotide polymorph-
isms (SNP) in the PAI-1 gene have been described
[14,15]. Association studies have shown that polymorph-
isms located in the promoter region of PAI-1 gene shows
a relationship with the concentrations of lipids (low
HDL) in Mexico-American population [16,17]. One of
the polymorphisms in the promoter PAI-1 gene is the
-844 G/A polymorphism, which has been associated with
risk factors such as increased plasma levels of PAI-1, glu-
cose, insulin resistance, triglycerides and low HDL, as
well as with several diseases including deep vein throm-
bosis, coronary artery disease, rheumatoid arthritis and
systemic lupus erithematosus [18-21]. Other SNP that is
interesting is the HindIII C/G polymorphism located in
the 3’ untranslated region (UTR) of PAI-1 gene, which
has been related to high levels of cholesterol and insulin
in myocardial infarction patients [22].
Based on this knowledge, both PAI-1 polymorphisms are
good candidates that might contribute to the pathological
features associated to the MetS. Therefore, we designed
this study to analyze allele and genotype frequencies of
-844 G/A and HindIII C/G PAI-1 polymorphisms and its
association with MetS and its components in a sample of
Mexican Mestizo children.
Methods
Patients and healthy subjects
All children enrolled in the study were of Mexican Mes-
tizo population born in the State of Guerrero, Mexico,
with a family history of ancestors, at least back to the
third generation born in our State. This cross-sectional
study was carried out between June and December
2008. Participants were recruited of three schools in the
urban area from Chilpancingo, Guerrero, Mexico. The
total group included 100 children with age range 6-11
years, divided in two groups: a) 48 children diagnosed
with MetS and b) 52 children metabolically healthy
without any clinical or biochemical alteration. The chil-
dren with one or two clinic or metabolic alterations
were excluded.
Informed written consent was obtained from all parents
or guardians before enrollment of children in the study.
Approval for the study was obtained from the Research
Ethics Committee of the University of Guerrero according
to the ethical guidelines of 2008 Declaration of Helsinki.
Clinical and anthropometric measurements
Body weight was determined using a Tanita body compo-
sition monitor (Tanita BC-553, Arlington, USA) and
height was measured to the nearest 0.1 cm using a stadi-
ometer (Seca, Hamburg, Germany). From these measure-
ments, body mass index was calculated (BMI = weight/
height
2,k g / m
2). The circumferences were measured by
duplicate using a diameter tape accurate to within ± 0.1
cm (Seca 201, Hamburg, Germany). Waist circumference
was measured at the level of the umbilicus and the super-
ior iliac crest. The measurement was made at the end of a
normal expiration while the subjects stood upright, with
feet together and arms hanging freely at the sides. Hip cir-
cumference was measured at the maximum point below
the waist, without compressing the skin. The waist-to-hip
ratio was calculated as waist/hip. The thickness of four
skinfolds was measured to the nearest 0.1 mm, in dupli-
cate, using skinfold caliper (Dynatronics Co, Salt Lake
City, USA): triceps, biceps, subscapular and suprailiac. The
duplicate measures were averaged.
Blood pressure (BP) was measured on the right arm of
children seated and a rest for at least 5 min. Two consecu-
tive measures were obtained at 1-min interval with an
aneroid sphygmomanometer (Riester CE 0124, Jungingen,
Germany). Hypertension was defined as the average of the
two measurements where the systolic BP (SBP) or diastolic
BP (DBP) is ≥ 95th percentile for age and gender was
determined [23]. The classification of obesity was made
using the 2000 Center for Disease Control and Prevention
growth charts defined as normal weight 5
th-85
th percen-
tiles and obesity ≥ 95th percentile [24].
Biochemical measurements and definitions
A blood sample was obtained from each child from ante-
cubital venipuncture after overnight fast. Total serum cho-
lesterol, triglycerides, HDL-cholesterol, LDL-cholesterol
and glucose levels were obtained using a semi-automated
equipment (COBAS MIRA), insulin levels were deter-
mined by immunoenzymatic assay (GenWay INS-EASIA
kit).
The homeostasis model assessment of insulin resistance
(HOMA-IR score) was used to determine insulin resistance
in children; this score was calculated with the following
formula: fasting serum insulin (μU/mL) × fasting plasma
glucose (mmol/L)/22.5 taking scores ≥ 75
th percentile
(HOMA-IR ≥ 2 . 4 )a st h ep r e s e n c eo fi n s u l i nr e s i s t a n c e .
We employed International Diabetes Federation pro-
posal for metabolic syndrome definition in children
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[25]. In this study, MetS was defined as the presence of
three or more of the following criteria: fasting glucose
levels ≥ 100 mg/dL, triglycerides ≥ 150 mg/dL, HDL-
cholesterol < 40 mg/dL, obesity BMI ≥ 95
th percentile,
SBP and DBP ≥ 95
th percentile and insulin resistance
HOMA-IR ≥ 2.4.
Genotyping of -844 G/A and HindIII C/G PAI-1
polymorphism
The genomic DNA (gDNA) was isolated from peripheral
blood leukocyte according to the salting out method
[26]. The -844 G/A and HindIII C/G PAI-1 single
nucleotide polymorphisms were analyzed by polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP). Amplification of -844 PAI-1 promoter
region was done in a thermal cycler (Techne, TC-312,
Cambridge, UK) using the following oligonucleotides:
5’CAGGCTCCCACTGATTCTAC3’ (Forward) and
5’GAGGGCTCTCTTGTGTCAAC3’ (Reverse) [27]. PCR
was carried out in a final volume of 20 μL containing
1 μgo fg D N A ,2 0μM of each oligonucleotide, 1.25 U/
μL Taq DNA polymerase, supplied buffer enzyme 1×,
MgCl2 2.5 mM, and 2.5 mM of each deoxynucleotide
triphosphate (dNTP) (Invitrogen Life Technologies,
Carlsbad, Ca). PCR reaction was performed by initial
denaturation at 94°C for 3 min, 30 cycles of amplifica-
tion at 94°C for 30 seconds for denaturation, 60°C for
30 seconds for annealing, and 72°C for 30 seconds for
extension. Finally, 72°C for 1 min was used for ending
extension, resulting in a 510 base pair amplified frag-
ment analyzed on a 6% polyacrylamide gel stained with
silver nitrate. Amplified fragments of -844 PAI-1 poly-
morphism were digested for 1 hour at 37°C with 3 U of
XhoI (New England Biolabs, Beverly, Mass.) restriction
enzyme. Afterward, restriction fragments were analyzed
by electrophoresis on a 6% polyacrylamide gel stained
with silver nitrate. The G/G wild-type genotype was
digested and appeared as 364 and 146 bp fragments,
whereas the A/A polymorphic genotype (absence of the
XhoI site) migrated as a 510 bp fragment.
The HindIII polymorphism was detected using the fol-
lowing oligonucleotides: 5’GCCTCCAGCTACCGT-
TATTGTACA3’ (Forward) and 5’CAGCCTAAACAACA
GAGACCCC3’ (Reverse) [28]. PCR was carried out in a
final volume of 20 μLc o n t a i n i n g1μg of gDNA, 3 μMo f
each oligonucleotide, 1.25 U/μL Taq DNA polymerase,
supplied buffer enzyme 1×, MgCl2 1.5 mM, and 2.5 mM
of each dNTP (Invitrogen Life Technologies). PCR reac-
tion was performed by initial denaturation at 94°C for
3 min, 30 cycles of amplification at 94°C for 30 seconds
for denaturation, 60°C for 30 seconds for annealing, and
72°C for 30 seconds for extension. Finally, 72°C for 1 min
was used for ending extension, resulting in a 755 bp
amplified fragment analyzed on a 6% polyacrylamide gel
stained with silver nitrate. Amplified fragments of Hind III
PAI-1 polymorphism were digested for 1 hour at 37°C
with 5 U of HindIII (New England Biolabs) restriction
enzyme. Afterward, restriction fragments were analyzed by
electrophoresis on 6% polyacrylamide gel stained with sil-
ver nitrate. The C/C wild-type genotype was digested and
appeared as 567 and 188 bp fragments, whereas the G/G
polymorphic genotype (absence of HindIII site) migrated
as a 755 bp fragment. To confirm the results, genotyping
of both polymorphisms were done in duplicate in all cases
and were randomly selected only a few -844 and HindIII
PAI-1 genotypes for sequencing.
Statistical analysis
Statistical analysis was performed using the statistical soft-
ware STATA v 9.2. For the descriptive analysis, nominal
variables were expressed as frequencies, continuous vari-
ables normally distributed as mean and standard deviation,
and those not normally distributed were expressed as
medians and percentile 5 and 95. We determined geno-
type and allele frequencies for the polymorphisms -844
and HindIII PAI-1 gene by direct counting, we performed
chi-square test to compare proportions between groups
(MetS vs. metabolically healthy) and to evaluate the
Hardy-Weinberg equilibrium. The linkage disequilibrium
between both SNPs was determined as D’.
The significance of the differences between the bio-
chemical and anthropometric parameters by genotypes
(G/G vs. GA + AA -844 and C/C vs. C/G + G/G HindIII
PAI-1) was determined using student t test and by Mann
Whitney. To evaluate the effect of polymorphism we used
models of linear and logistic regression adjusted by gender
and age. Differences were considered statistically signifi-
cant at p < 0.05.
Results
The present study included 100 Mexican Mestizo chil-
dren of both genders, aged 6 to 11 years. Children were
classified into two groups made up of 52 children meta-
bolically healthy and 48 children with MetS, according
the criteria mentioned above. The prevalence of compo-
nents de MetS in the cases group was: 33.04% for obe-
sity + hyperglycemia + high triglycerides, 29.79% for
obesity + hyperglycemia + high triglycerides + low
HDL-cholesterol, 14.89% for obesity + hyperglycemia +
low HDL-cholesterol and others combinations with
minor prevalence (data no shown).
In this study, both polymorphisms evaluated were in
Hardy-Weinberg equilibrium (c
2 = 0.005; p = 1.0 for -844
G/A polymorphism, and c
2 = 0.62; p =0 . 6 6f o rHindIII C/
G polymorphism). The linkage disequilibrium (D’)
between both SNPs was 0.81. The distribution of allele
and genotype frequencies between the two groups did not
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ism, but for the -844 G/A polymorphism we observed a
significant differences in genotype (p = 0.034) and allele
frequencies (p = 0.015) between the two groups, with an
OR of 2.79 (95% CI, 1.11 to 7.08) for the G/A genotype
and an OR of 2.2 (95% CI, 1.10 to 4.43) for A allele, which
indicates that children who were carriers of the risk A
allele, have 2.2 fold more susceptibility to present MetS,
and in children carrying the G/A genotype the risk
increases to 2.79 fold (Table 1).
Demographic, clinical and biochemical variables were
compared by gender in all children. Only was observed a
difference, the boys had higher fasting glucose levels than
girls (median, 97 vs. 93 mg/dL; p = 0.04) (Table 2).
Demographic, clinical and biochemical variables were
compared by genotypes of both PAI-1 polymorphisms
according to a dominant genetic model. For the -844 G/
A polymorphism the G/A and A/A genotypes were
grouped for this genetic model, the -844 G/A + A/A
group showed a high prevalence of obesity (60%; p =
0.01), an increase in thickness of the biceps (16 mm; p =
0.05), triceps (16 mm; p = 0.01) and subscapular skinfolds
(15 mm; p = 0.03) and arm circumference (22 cm; p =
0.04), as well as decrease in HDL levels (39 mg/dL; p =
0.04) in comparison with G/G group (Table 3). To esti-
mate in all children, the association of -844 G/A + A/A
genotypes with demographic, clinical and biochemical
variables that showed significant differences or tenden-
cies, we used logistic regression models adjusted by age
and gender. The -844 G/A + A/A genotypes were asso-
ciated with increase in plasma triglycerides levels (OR =
2.6; 95% CI, 1.16 to 6.04; p = 0.02), decrease in plasma
HDL-cholesterol levels (OR = 2.4; 95% CI, 1.06 to 5.42;
p = 0.03) and obesity (OR = 2.6; 95% CI, 1.17-5.92; p =
0.01) (Table 4). However, we did not find a relationship
with biceps, triceps and subscapular skinfolds as well as
arm circumference (data no shown).
For the HindIII C/G polymorphism, when the C/G and
G/G genotypes were grouped, the C/G + G/G group
showed only an increase in plasma total cholesterol levels
(179 mg/dL; p = 0.02) in comparison with C/C group
(165 mg/dL).
Discussion
This study shows the association of two polymorphisms
in the PAI-1 gene with the development of MetS and its
Table 1 Genotype and allele frequencies of -844 and HindIII PAI-1 polymorphisms in cases and controls
Polymorphism Metabolic
syndrome
%( n = 48)
Metabolically
healthy
% (n = 52)
P value* OR CI (95%); p value
-844 G/A PAI-1
Genotype
G/G
§ 40 (19) 65 (34) 0.034 1.0
G/A 52 (25) 31 (16) 2.8 (1.11-7.08); 0.015
A/A 8 (4) 4 (2) 3.6 (0.45-42.06); 0.15
Allele
G 66 (63) 81 (84) 0.015 1.0
A 34 (33) 19 (20) 2.2 (1.10-4.43); 0.015
Genetic model
Do
G/G
§ 40 (19) 65 (34) 0.01 1.0
G/A + A/A 60 (29) 35 (18) 2.9 (1.18-7.05); 0.009
HindIII C/G PAI-1
Genotype
C/C
§ 50 (24) 63 (33) 0.28 1.0
C/G 44 (21) 35 (18) 1.6 (0.65-3.95); 0.25
G/G 6 (3) 2 (1) 4.12 (0.30-222.9); 0.22
Allele
C 72 (69) 81 (84) 0.13 1.0
G 28 (27) 19 (20) 1.64 (0.8-3.36); 0.13
Genetic model
Do
C/C
§ 50 (24) 63 (33) 0.17 1.0
C/G + G/G 50 (24) 37 (19) 1.73 (0.75-4.17); 0.13
*Chi square test c
2; OR = odds ratio; CI = confidence interval; Do = dominant model
§Reference category
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mia in a Mexican children population.
Regarding the distribution of genotype and allele fre-
quencies of both polymorphisms, for the HindIII C/G
polymorphism we found a high frequency of C allele, simi-
lar to previous reports in Mexican mestizo population and
Caucasian population, however the G allele frequency was
lower in Mexican population [18,21,29]. On the other
hand, the -844 G/A polymorphism we observed that is dis-
tributed inversely to those reported in Caucasian popula-
tions, in which the A allele is more frequent than the G
allele [12,18,19]. In our study this polymorphism had a
high frequency of G allele and a lower frequency of A
allele, consistent with already reported frequencies in pre-
vious studies in Mexican mestizo population [20,30], sug-
gesting that in the Mexican population there is a high
frequency of allele G.
According to our results, the differences observed in
the distribution of -844 G/A polymorphism may be
attributed to the racial influence, which is central to the
heterogeneous distribution of genetic polymorphisms. It
is known that the Mexican population originated from a
m i x t u r eo fE u r o p e a n( 4 . 2t o7 0 . 8 % )a n dA f r i c a n( 0 . 9t o
40.5%) populations with Amerindian groups (27.6 to
94.5%), giving origin to the Mexican mestizo population,
which has a higher genetic diversity in the distribution
of this and other polymorphisms [31]. This can explain
the differences in the distribution of genotypic and alle-
lic frequencies of our population with other populations
in the world.
As an important finding, in our study we found signifi-
cant differences in the distribution of genotype and allele
frequencies of -844 G/A polymorphism in both groups,
determining an OR of 2.2 for A allele, and an OR of 2.79
for G/A genotype, which indicates that children who
carry the A allele are 2.2 fold more susceptible to develop
MetS and children who are carriers of the G/A genotype
have a 2.79 fold increased risk of developing the syn-
drome, compared to those who are carriers of G allele
and G/G genotype. These results obtained in our study
a r es i m i l a rt ot h o s er e p o r t e di nap r e v i o u ss t u d yd o n ei n
Caucasian population in which A/A genotype was asso-
ciated with the susceptibility of developing MetS (OR,
4.87; p < 0.001) [12]. These consistent results reported in
different populations may be due to the effect of the
polymorphism on the levels of the protein, since it has
been reported that the base change of G to A at position
-844 of the promoter PAI-1 gene generates a binding site
consensus sequence for Ets nuclear protein, which could
be involved in regulating gene expression and influencing
the increase in PAI-1 plasma protein levels [32,33].
While for the HindIII C/G polymorphism not significant
differences were found in genotype and allele distribu-
tion, but it has been reported that the base change of C
to G at the 3’ UTR of PAI-1 gene might plays an impor-
tant role in the disruption of the translational regulation
process and cause changes in the translational levels of
messenger ribonucleic acid (mRNA) in both physiological
and pathological conditions, resulting in an increase in
PAI-1 plasma protein levels [34].
We described for first time in Mexican children that
-844 G/A polymorphism contribute to a significant
increase in subcutaneous fat, increasing the risk of devel-
oping obesity (OR, 2.6; p = 0.01) in children who are car-
riers of the G/A and A/A genotypes. A possible
explanation for this finding could be that the -844 G/A
polymorphism contribute to the large amount of PAI-1
produced by adipose tissue expansion, as well as the
increase of obesity. Studies of PAI-1 knockout mice have
shown an effect of PAI-1 on weight gain and increased
adipose cellularity associated with high-fat dieting [35].
Besides, studies in which the PAI-1 gene was disrupted in
ob/ob mice show a reduction of adiposity in these mice.
This suggests that PAI-1 gene can control fat mass,
although the mechanism of action is not yet known, may
be PAI-1 gene can control fat mass at least in part, by
Table 2 General characteristics by gender in all children
Gender
Variables Boys
n =4 8
Girls
n =5 2
p value
Age (years)
c 9 (6-11) 9 (6-11) 0.1
BMI (kg/m
2)
c 18 (14-28) 18 (14-26) 0.1
Obesity (%) 0.5
Yes 24 (50) 23 (44)
No 24 (50) 29 (56)
Circumferences
Waist (cm)
c 67 (55-90) 66 (56-85) 0.2
Arm (cm)
c 21 (17-28) 20 (16-29) 0.4
Skinfolds
Biceps (mm)
b 15 ± 4.7 16 ± 4.4 0.2
Triceps (mm)
c 14 (10-22) 15(9-22) 0.5
Subscapular (mm)
c 13 (6-22) 15(6-22) 0.4
Biochemical measurements
Glucose (mg/dL)
c 97 (75-112) 93(70-112) 0.04
Total cholesterol (mg/dL)
b 175 ± 30 168 ± 29 0.2
Triglycerides (mg/dL)
c 101(36-204) 102 (38-200) 0.8
HDL-C (mg/dL)
c 43(25-98) 46 (23-99) 0.9
Insulin (μU/mL)
c 6 (0.8-31.3) 8 (0.4-21) 0.8
HOMA
c 1.5 (0.18-7.2) 1.7 (0.08-5.1) 0.6
Insulin resistance
a 0.07
Yes 13 (41) 15 (37)
No 19 (59) 25 (63)
a) Data provided in n and percentages. Chi square test; b) Data provided in
means ± SD. Student’s t test; c) Data provided in median and percentile 5-95.
Mann-Whitney test
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-844 G/A PAI-1 HindIII C/G PAI-1
Variables G/G
n =5 3
G/A + A/A
n =4 7
p value C/C
n =5 7
C/G + G/G
n =4 3
p value
Age (years)
c 9 (6-11) 9 (6-11) 0.22 9 (6-11) 9 (6-11) 0.08
Gender (%)
a 0.30 0.06
Male 28 (53) 20 (43) 32 (56) 16 (37)
Female 25 (47) 27 (57) 25 (44) 27 (63)
BMI (kg/m
2)
c 17 (13.7-26.6) 20 (15.1-27.5) 0.09 18 (14-29) 20 (15-26) 0.67
Obesity (%) 0.01 0.25
Yes 19 (36) 28 (60) 24 (42) 23 (53)
No 34 (64) 19 (40) 33 (58) 20 (47)
Circumferences
Waist (cm)
c 66 (54-87) 69 (57-89) 0.22 67 (54-90) 66 (57-88) 0.84
Arm (cm)
c 20 (16-28) 22 (17-29) 0.04 21 (16-30) 21 (17-28) 0.68
Skinfolds
Biceps (mm)
b 15 ± 4.32 16 ± 4.70 0.05 15 ± 4.2 16 ± 4.9 0.27
Triceps (mm)
c 13 (9-22) 16 (10-20.5) 0.01 14 (9.5-21.5) 15 (9-22) 0.75
Subscapular (mm)
c 13 (5.5-22) 15 (8.5-22) 0.03 14 (6-25) 13 (6-22) 0.85
Biochemical measurements
Glucose (mg/dL)
c 95 (72-116) 96 (72-112) 0.38 95 (72-110) 95 (72-112) 0.59
Total cholesterol (mg/dL)
b 168 ± 27.91 175 ± 31.05 0.20 165 ± 29.6 179 ± 28 0.02
Triglycerides (mg/dL)
c 86 (38-225) 150 (36-200) 0.09 91 (29-200) 116 (38-204) 0.13
HDL-C (mg/dL)
c 53 (25-102) 39 (23-89) 0.04 49 (21-99) 40 (25-98) 0.54
Insulin (μU/mL)
c 5 (0.09-27.5) 10 (1.25-22.7) 0.10 7 (0.7-25) 7 (0.5-23) 0.91
HOMA
c 0.5 (0-6.04) 1 (0-5.5) 0.30 1.62 (0.1-6.0) 1.8 (0.1-6.0) 0.89
Insulin resistance
a 0.19 0.78
Si 9 (17) 13 (28) 12 (29) 10 (32)
No 44 (83) 34 (72) 29 (71) 21 (68)
a) Data provided in n and percentages. Chi square test; b) Data provided in means ± SD. Student’s t test; c) Data provided in median and percentile 5-95. Mann-
Whitney test
Table 4 Association of G/A + A/A genotypes of -844 PAI-1 polymorphism with obesity and lipid levels
-844 PAI-1
Genotypes
Obesity OR (95% CI) p*
value
<9 5
th percentile % (n = 58) ≥ 95
th percentile % (n = 42)
G/G
§ 64 (34) 40 (19) 1
G/A + A/A 36 (19) 60 (28) 2.6 1.17-5.92 0.01
Plasma triglycerides levels
< 150 mg/dL % (n = 61) > 150 mg/dL % (n = 39)
G/G
§ 62 (38) 38 (15) 1
G/A + A/A 38 (23) 62 (24) 2.6 1.16-6.04 0.02
Plasma HDL-cholesterol levels
> 40 mg/dL % (n = 58) < 40 mg/dL % (n = 42)
G/G
§ 68 (36) 32 (17) 1
G/A + A/A 47 (22) 53 (25) 2.4 1.06-5.42 0.03
*Chi square test,
§ Reference category, OR = odds ratio, CI = confidence interval
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on the expression of genes such as tumour necrosis factor
alpha (TNF-a) and transforming growth factor beta (TGF-
b), leptin and insulin [36].
In addition the effect on the increase in adipose tissue,
there was an association of G/A and A/A genotypes of
-844 G/A polymorphism with increased triglyceride
levels and decreased HDL-C levels, which indicates that
those children who are carriers of these genotypes, have
an increase in the risk to develop atherogenic dyslipide-
mia compared with genotype G/G. In the case of HindIII
C/G polymorphism, C/G and G/G genotypes were asso-
ciated with a raise of total cholesterol explaining 8% of
the variability of their plasma concentration, influencing
along with -844 G/A polymorphism to the development
of atherogenic profile that characterizes the MetS. It has
been reported that a very-low-density lipoprotein
(VLDL)-responsive element in the PAI-1 promoter could
be responsible for the effect of plasma lipids on PAI-1
expression [14]. Therefore, the increase in PAI-1 levels
may contribute to the development of obesity and
atherogenic dyslipidemia, and PAI-1 may be a causal link
between obesity and cardiovascular disease.
The -844 G/A and HindIII C/G PAI-1 single nucleotide
polymorphisms have not been associated with PAI-1
levels. Several adult studies showed that an increase in the
level of PAI-1 was related to the genotype PAI-1 4 G/5 G
polymorphism [37,38]. However, in children some infor-
mation is available on the influence of the 4 G/5 G poly-
morphism on PAI-1 levels or with others obesity-related
phenotypes. In Children with obesity, Estelles et al. [39]
observed no influence of the 4 G/5 G polymorphism on
PAI-1 levels. Moreover, no influence of the PAI-1 4G / 5G
polymorphism on lipid and glucose metabolism para-
meters was observed in Turkish obese children [40,41].
A limitation of this study is the small number of sample,
even though is a sample with children that were recruited
with precise selection criteria and the control group did
not have any of the components included in the definition
of MetS. In addition, few studies of genetic association of
PAI-1 gene with MetS have been conducted in children.
Other limitation of this study is that lack of replication,
the replication of genetic associations in independent
populations is essential to reduce the number of false-
positive results and to further define the role of these var-
iants in the susceptibility to complex disease as MetS.
Although our study found an association of -844 G/A
polymorphism with the MetS and its components such
as obesity and a atherogenic dyslipidemia characterized
by hypertriglyceridemia and low HDL-cholesterol, and
the HindIII C/G polymorphism with increased plasma
levels of total cholesterol, other of the limitations is that
PAI-1 plasma levels were not measured; therefore the
association of -844 G/A and HindIII C/G polymorphisms
with PAI-1 levels remains uncertain in our population.
Therefore it is necessary to determine PAI-1 plasma
levels in future studies in Mexican children.
Conclusions
In summary, this study provide evidence that the -844 G/
A PAI-1 polymorphism is related with the risk of develop-
ing MetS, obesity and atherogenic dyslipidemia, and the
HindIII C/G PAI-1 polymorphism is associated with
increased total cholesterol levels, which contributes to the
pathogenesis of MetS.
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